

**IN THE CLAIMS:**

Please replace all prior versions of claims 10-28 with the version of claims 10-28 set forth below:

1.-9. (Canceled).

10. (Currently Amended) A vaccine composition comprising at least one ~~particulate~~ immunogen and an adjuvanting amount of B subunits of heat-labile enterotoxin ~~characteristic of E. coli~~, wherein said B subunits are free of A subunit and toxic LT holotoxin, ~~and wherein said at least one particulate immunogen is not covalently coupled to said B subunits, and wherein said at least one immunogen is in the form of aggregates, clusters, micelles, virosomes, or rosettes, or a mixture of two or more of the foregoing.~~

11. (Previously Presented) The vaccine composition according to claim 10, wherein said B subunits are prepared by recombinant DNA methods.

12. (Currently Amended) The vaccine composition according to claim 10 or claim 11, wherein the at least one ~~particulate~~ immunogen comprises a viral antigen, a bacterial antigen, or a fungal antigen, or a combination thereof.

4 13. (Currently Amended) The vaccine composition according to claim 10,  
wherein the at least one ~~particulate~~ immunogen is ~~derived~~ from at least one infective  
agent which causes a disease which is transmitted by mucosal infection.

5 14. (Currently Amended) The vaccine composition according to claim 10,  
wherein the at least one ~~particulate~~ immunogen is ~~characteristic of~~ from a micro-  
organism which causes a disease which is transmitted by mucosal infection.

6 15. (Currently Amended) The vaccine composition according to claim 10 or  
claim 11, wherein the at least one ~~particulate~~ immunogen provides immunization  
against a disease which is transmitted by mucosal infection.

7 16. (Currently Amended) The vaccine composition according to claim 15,  
wherein the at least one ~~particulate~~ immunogen comprises at least one influenza  
antigen.

8 17. (Currently Amended) A method for the induction of a systemic  
immunoglobulin response against at least one immunogen in a human or animal host in  
need of such induction, comprising:

administering to mucosal tissue of the host said at least one immunogen in the  
particulate form of aggregates, clusters, micelles, virosomes, or rosettes, or a mixture of  
two or more of the foregoing, and an adjuvanting amount of B subunits of heat-labile

enterotoxin ~~characteristic~~ of *E. coli*, wherein said B subunits are free of A subunit and toxic LT holotoxin, wherein said at least one immunogen together with said B subunits is present in sufficient quantity for said induction, and wherein said at least one immunogen is not covalently coupled to said B subunits.

9 18. (Currently Amended) A method for ~~the induction of a common mucosal-immune response~~ activating the common mucosal immune system against at least one immunogen in a human or animal host in need of such ~~induction~~ activating, comprising:  
administering to mucosal tissue of the host said at least one immunogen in the particulate form of aggregates, clusters, micelles, virosomes, or rosettes, or a mixture of two or more of the foregoing, and an adjuvanting amount of B subunits of heat-labile enterotoxin ~~characteristic~~ of *E. coli*, wherein said B subunits are free of A subunit and toxic LT holotoxin, wherein said at least one immunogen together with said B subunits is present in sufficient quantity for said ~~induction~~ activating, and wherein said at least one immunogen is not covalently coupled to said B subunits.

10 19. (Currently Amended) A method of preparing a vaccine for the induction of a systemic immunoglobulin response against at least one immunogen in a human or animal host upon mucosal administration of said vaccine, comprising:  
combining said at least one immunogen in the particulate form of aggregates, clusters, micelles, virosomes, or rosettes, or a mixture of two or more of the foregoing, and an adjuvanting amount of B subunits of heat-labile enterotoxin ~~characteristic~~ of *E.*

*coli*, wherein said B subunits are free of A subunit and toxic LT holotoxin, wherein said at least one immunogen together with said B subunits is present in sufficient quantity for said induction, and wherein said at least one immunogen is not covalently coupled to said B subunits.

11 20. (Currently Amended) A method of preparing a vaccine for ~~the induction of~~  
~~a common mucosal immune response~~ activating the common mucosal immune system  
against at least one immunogen in a human or animal host upon local mucosal  
administration of said vaccine, comprising:

combining said at least one immunogen in the particulate form of aggregates,  
clusters, micelles, virosomes, or rosettes, or a mixture of two or more of the foregoing,  
and an adjuvanting amount of B subunits of heat-labile enterotoxin ~~characteristic of E.~~  
*coli*, wherein said B subunits are free of A subunit and toxic LT holotoxin, wherein said  
at least one immunogen together with said B subunits is present in sufficient quantity for  
said ~~induction~~ activating, and wherein said at least one immunogen is not covalently  
coupled to said B subunits.

12 21. (Currently Amended) A vaccine comprising at least one ~~particulate~~  
immunogen and an adjuvanting amount of B subunits of enterotoxin, wherein said B  
subunits are free of A subunit and toxic LT holotoxin, ~~and~~ wherein said at least one  
~~particulate~~ immunogen is not covalently coupled to said B subunits, and wherein said at

least one immunogen is in the form of aggregates, clusters, micelles, virosomes, or rosettes, or a mixture of two or more of the foregoing.

13 22. (Currently Amended) A vaccine comprising at least one ~~particulate~~ immunogen and an adjuvanting amount of B subunits of cholera toxin, wherein said B subunits are free of A subunit and toxic CT holotoxin, ~~and~~ wherein said at least one ~~particulate~~ immunogen is not covalently coupled to said B subunits, and wherein said at least one immunogen is in the form of aggregates, clusters, micelles, virosomes, or rosettes, or a mixture of two or more of the foregoing.

14 23. (Currently Amended) A vaccine comprising at least one ~~particulate~~ immunogen and an adjuvanting amount of B subunits chosen from enterotoxin and cholera toxin, wherein said B subunits are free of A subunit, toxic LT holotoxin, and toxic CT holotoxin, ~~and~~ wherein said at least one ~~particulate~~ immunogen is not covalently coupled to said B subunits, and wherein said at least one immunogen is in the form of aggregates, clusters, micelles, virosomes, or rosettes, or a mixture of two or more of the foregoing.

12  
15 24. (Currently Amended) The vaccine according to claim 21, wherein the at least one ~~particulate~~ immunogen comprises at least one influenza antigen.

<sup>13</sup>  
16 25. (Currently Amended) The vaccine according to claim 22, wherein the at least one ~~particulate~~ immunogen comprises at least one influenza antigen.

<sup>14</sup>  
17 26. (Currently Amended) The vaccine according to claim 23, wherein the at least one ~~particulate~~ immunogen comprises at least one influenza antigen.

<sup>1</sup>  
<sup>18</sup> 27. (Currently Amended) The vaccine composition of claim 10, wherein the at least one ~~particulate~~ immunogen comprises micelles, rosettes, or a mixture of micelles and rosettes.

<sup>12</sup> <sup>13</sup>  
<sup>19</sup> <sup>14</sup> 28. (Currently Amended) The vaccine of any one of claim 21, claim 22, and claim 23, wherein the at least one ~~particulate~~ immunogen comprises micelles, rosettes, or a mixture of micelles and rosettes.